The GLP-1 Market is expanding as therapeutic applications move beyond diabetes into obesity and cardiovascular disease. Valued at USD 52.82 billion in 2025, the GLP-1 Market is projected to reach USD 58.48 billion in 2026 and USD 133.92 billion by 2034, growing at a CAGR of 10.9% during the forecast period 2026–2034. Key players include AstraZeneca, Boehringer Ingelheim, D&D Pharmatech, Eli Lilly, Hanmi Pharmaceutical, Novo Nordisk, Pfizer, Roche, Sanofi, and Tonghua Dongbao Pharmaceutical.

Type 2 Diabetes Burden Anchors GLP-1 Market Demand

The rising prevalence of type 2 diabetes remains the primary demand driver. According to the WHO, approximately 830 million people worldwide had diabetes in 2022, and over 95% of cases were type 2. The International Diabetes Federation projects 643 million cases by 2030 and 783 million by 2045. GLP-1 receptor agonists offer dual benefits by improving insulin secretion and suppressing glucagon release in a glucose-dependent manner, which aligns with current clinical management needs. These therapies play a central role in improving glycemic control and reducing cardiovascular risk, and their ability to address both early-stage and progressive disease reinforces their importance in diabetes care. In the United States, May 2024 CDC data show diabetes affects 11.6% of the population, or 38.4 million people, while 38% of adults, or 97.6 million, have prediabetes.

Obesity Treatment Emerges as the Largest Indication

By target indication, the obesity segment held the largest share in 2025. A May 2025 WHO report found that 2.5 billion adults worldwide were overweight in 2022, including 890 million living with obesity. Obesity is a major risk factor for type 2 diabetes, cardiovascular diseases, and other comorbidities, creating demand for therapies that manage multiple conditions at once. GLP-1 therapies help regulate appetite and food intake and support sustainable weight management, giving them a twofold benefit in metabolic and weight-related disease. Growing clinical acceptance and expanding regulatory approvals for obesity indications have reinforced the segment's dominance, making obesity treatment a central growth pillar of the GLP-1 Market.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/glp-1-market

Long-Acting and Oral Formulations Improve Patient Compliance

By type of agonist, the long-acting GLP-1 agonist segment dominated in 2025 because of its superior dosing convenience, improved patient observation, and sustained therapeutic efficacy. These formulations are often administered once weekly, which reduces treatment burden and improves long-term compliance. They also provide extended glycemic control and cardiovascular benefits, making them a preferred choice among healthcare providers. By route of administration, oral GLP-1 therapies are expected to witness faster growth during 2026–2034. Rising demand for noninvasive, patient-friendly options and improved drug delivery technologies are enabling oral formulations with efficacy comparable to injectable counterparts. This shift is expected to expand market reach, especially in primary care settings and among patients with injection-related hesitation. By type of molecule, the biologics segment is also expected to grow substantially, supported by strong clinical performance and long half-life properties.

Regional Outlook and Competitive Positioning

North America dominated the global revenue share in 2025, supported by high disease prevalence, advanced healthcare infrastructure, early adoption of novel therapies, and favorable reimbursement policies. The US held the largest share within the region. Asia Pacific is projected to record the fastest growth, driven by rapid growth in lifestyle-related diseases and improving healthcare access. An ICMR study cited in the report states that India has 101 million diabetes cases. Europe is also expected to record substantial growth, supported by structured disease management programs and favorable reimbursement schemes.

Major players such as Novo Nordisk, Eli Lilly, and AstraZeneca are making strategic investments to expand their product lines in obesity and type 2 diabetes. Innovations such as oral formulations and dual-target agonists are reshaping competitive positioning, and patent expiries are creating opportunities for generics. The ADA's 2026 Standards are expanding the relevance of GLP-1-based therapies across diabetes, obesity, and related metabolic care, strengthening long-term commercial demand. High drug cost and affordability challenges remain the key restraint.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market